Immune checkpoint inhibitors and EGFR-TKIs as adjuvant/neoadjuvant therapies for resectable non-small cell lung cancer a systematic review
The ESP Coordinating Center (ESP CC) is responding to a request from the VA National Oncology Program Office for a synthesis of evidence on the efficacy and safety of immune checkpoint inhibitors (ICIs) and epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) as adjuvant or neoadj...
Main Authors: | , |
---|---|
Corporate Authors: | , |
Format: | eBook |
Language: | English |
Published: |
Washington, DC
Department of Veterans Affairs, Veterans Health Administration, Health Services Research & Development Service
2023, April 2023
|
Series: | Evidence synthesis program
|
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | The ESP Coordinating Center (ESP CC) is responding to a request from the VA National Oncology Program Office for a synthesis of evidence on the efficacy and safety of immune checkpoint inhibitors (ICIs) and epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) as adjuvant or neoadjuvant therapies for resectable non-small cell lung cancer (NSCLC), which is intended to inform the VHA's Oncology Clinical Pathways |
---|---|
Physical Description: | 1 PDF file (iv, i, 78 pages) illustrations |